Zhimeng Biopharma’s CB03-154 Receives CDE Approval for ALS Phase II/III Clinical Study
China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II/III clinical study...
Zhimeng Biopharma
Sage Group Expands into China’s Healthcare Market with Cenponts Healthcare Partnership
Sage Group, a UK-based financial advisory powerhouse, has announced a strategic foray into China’s burgeoning...
Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06
Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK...